Zenas Biopharma Inc (ZBIO)
Zenas Biopharma, Inc. (NASDAQ: ZBIO) is a clinical-stage biotechnology company focused on developing and commercializing immunology-based therapies. Its lead candidate, obexelimab, is a bifunctional monoclonal antibody designed to target CD19 and Fc?RIIb, with study efforts spanning immune and inflammatory diseases such as immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company’s pipeline also includes ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein intended to have an extended half-life; and ZB001, an anti-IGF-1R monoclonal antibody. Incorporated in 2019, the company was formerly known as Zenas BioPharma (Cayman) Limited and adopted its current name in August 2023. Zenas Biopharma is headquartered in Waltham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ZBIO
|
$31.96
|
-3.1% Downside
|
Fair
|
$42.13
|
27.7% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-4.9x
|
6.2x
|
—
|
1.938 B
|
1.617 B
|
12.1%
|
65.0%
|
1.2
|
—
|
49.5%
|
